Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
Mayo School of Graduate Medical Education, Mayo Clinic, Rochester, MN, USA.
Int J Dermatol. 2018 May;57(5):572-574. doi: 10.1111/ijd.13884. Epub 2018 Jan 16.
Calciphylaxis is a devastating multifactorial disorder of the subcutaneous fat that is known to be associated with hypercoagulability. Recent literature has proposed subclassifying patients with calciphylaxis as having warfarin-associated or warfarin-unassociated disease.
We aimed to determine whether patients with warfarin-associated calciphylaxis differ clinically from patients with warfarin-unassociated calciphylaxis.
We performed a subgroup analysis of patients with nonuremic calciphylaxis from a previously studied cohort and compared clinical and outcomes features of patients who were taking warfarin at the time of disease onset to those of patients who were not.
Nineteen patients with nonuremic calciphylaxis were identified, including 10 (53%) who had been on warfarin at the time of disease onset and 9 (47%) who had not. Of all clinical and outcomes parameters tested, no significant differences were detected between the two groups.
Though this study is limited by its retrospective nature and the relatively small number of patients studied, available data do not support subclassifying patients with nonuremic calciphylaxis as having warfarin-associated or warfarin-unassociated disease. Rather, the body of literature would suggest that identification and correction of underlying disorders of hypercoagulability should be prioritized.
钙化防御是一种已知与高凝状态相关的严重多因素皮下脂肪疾病。最近的文献提出将钙化防御患者细分为与华法林相关或与华法林无关的疾病。
我们旨在确定与华法林相关的钙化防御患者与与华法林无关的钙化防御患者在临床上是否存在差异。
我们对先前研究队列中患有非尿毒症性钙化防御的患者进行了亚组分析,并比较了发病时正在服用华法林的患者与未服用华法林的患者的临床和结局特征。
共确定了 19 例非尿毒症性钙化防御患者,其中 10 例(53%)在发病时正在服用华法林,9 例(47%)未服用。在所有测试的临床和结局参数中,两组之间未发现显著差异。
尽管这项研究受到回顾性性质和研究患者数量相对较少的限制,但现有数据不支持将非尿毒症性钙化防御患者细分为与华法林相关或与华法林无关的疾病。相反,文献综述表明,应优先确定和纠正潜在的高凝状态紊乱。